Cubist Pharmaceuticals Appoints Kenneth Martin to Board of Directors

  Cubist Pharmaceuticals Appoints Kenneth Martin to Board of Directors

Business Wire

LEXINGTON, Mass. -- September 25, 2013

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the appointment of
Kenneth J. Martin to its Board of Directors. Mr. Martin most recently served
as the Chief Financial Officer and Vice Chairman of Wyeth and currently serves
on the Board of WABCO Holdings, Inc.

“Ken Martin has an exceptional mix of global finance, industry and leadership
expertise that will be a valued asset to Cubist, and we are thrilled to have
him join our Board,” said Ken Bate, non-executive Chairman of the Board of
Directors of Cubist. “Importantly, Ken’s experience at Wyeth gives him an
important perspective as Cubist begins its next, exciting chapter focused on
global growth and continuing to drive significant shareholder value.”

Mr. Martin served as the Chief Financial Officer and Vice Chairman of Wyeth
(formerly American Home Products) from 2000 to 2007, before retiring in 2007.
Mr. Martin joined American Home Products in 1984 and held the positions
ofSenior Vice President of Finance, Executive Vice President and President
for American Home Food Products. He also served in a variety of senior roles
for Whitehall-Robins Healthcare, and became the Company’s President in 1997.
In 1998 he was named Senior Vice President and Chief Financial Officer of
Wyeth-Ayerst Pharmaceuticals, and in 2000 he was named Wyeth’s Senior Vice
President and Chief Financial Officer. Since 2007, Mr. Martin has served as a
member of the Board of Directors of WABCO Holdings, Inc., a leading global
supplier of technologies and control systems for the safety and efficiency of
commercial vehicles. He previously served as a member of the board of
directors of Talecris Biotherapeutics Holdings Corp from 2007 to 2011. He
earned his BBA in Accounting from Hofstra University.

About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
research, development, and commercialization of pharmaceutical products that
address significant unmet medical needs in the acute care environment. Cubist
is headquartered in Lexington, Mass. Additional information can be found at
Cubist’s web site at www.cubist.com.

Cubist Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements contained herein which do not describe
historical facts, including but not limited to, statements regarding our plans
to expand globally and continue driving shareholder value, are forward-looking
statements which involve risks and uncertainties that could cause actual
results to differ materially from those discussed in such forward-looking
statements. Such risks and uncertainties include: our ability to successfully
develop, gain marketing approval for and commercially launch our product
candidates for their planned indications and on the timelines that we expect;
our ability to discover, in-license or acquire new products and product
candidates; our ability to achieve and manage our growth in our business; and
those additional factors discussed in our most recent Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission. We caution investors
not to place considerable reliance on the forward-looking statements contained
in this press release. These forward-looking statements speak only as of the
date of this document, and we undertake no obligation to update or revise any
of these statements.

Contact:

Cubist Pharmaceuticals, Inc.
INVESTORS:
Eileen C. McIntyre, 781-860-8533
Vice President, Investor Relations
eileen.mcintyre@cubist.com
or
MEDIA:
Julie DiCarlo, 781-860-8063
Senior Director, Corporate Communications
julie.dicarlo@cubist.com
 
Press spacebar to pause and continue. Press esc to stop.